Biopharma CEOs Can’t Dodge Policy Questions as Trump Lobs Wrench into Earnings Season

By /

From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.

Scroll to Top